Do you want to read an article? Please log in or register.
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia
Leukemia
Related content
RECOMMENDED
Leukemia
IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics
★ 2
Recommended by
Prof. Dr Christoph Renner, Faculty Member
Blood.
Nadeu F, Royo R, Clot G, Duran-Ferrer M, Navarro A, Martin S, Lu J, Zenz T, Baumann TS, Jares P, Puente XS, Martin-Subero I, Delgado J, Campo E
doi: 10.1182/blood.2020008311.
Leukemia
TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
doi: 10.3324/haematol.2018.187583.
Leukemia
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)
Haematologica.
Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, Jasmin Bahlo, Sandra Robrecht, Eugen Tausch, Johannes Bloehdorn, Manuela Hoechstetter, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Michael Hallek, Hartmut Döhner, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos, Stephan Stilgenbauer
doi: 10.3324/haematol.2019.231027.
Leukemia
Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia
Leukemia.
Murphy EJ, Neuberg DS, Rassenti LZ, Hayes G, Redd R, Emson C, Li K, Brown JR, Wierda WG, Turner S, Greaves AW, Zent CS, Byrd JC, McConnel C, Barrientos J, Kay N, Hellerstein MK, Chiorazzi N, Kipps TJ, Rai KR
doi: 10.1038/leu.2017.34.
Leukemia
Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia
doi: 10.1002/ijc.31999.
RECOMMENDED
Leukemia
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia
★ 1
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
★ 2
Recommended by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.1182/blood.2019003453.
Leukemia
Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study
Haematologica.
Sutton LA, Ljungström V, Enjuanes A, Cortese D, Skaftason A, Tausch E, Stano Kozubik K, Nadeu F, Armand M, Malcikova J, Pandzic T, Forster J, Davis Z, Oscier D, Rossi D, Ghia P, Strefford JC, Pospisilova S, Stilgenbauer S, Davi F, Campo E, Stamatopoulos K, Rosenquist R, European Research Initiative on
CLL (ERIC).
doi: 10.3324/haematol.2019.234716.
RECOMMENDED
Further Publications
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
★ 3
Recommended by
Alexander Meisel, Faculty Member
J Clin Oncol.
Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Dubois J, Eldering E, Mellink C, Van Der Kevie-Kersemaekers AM, Kim SY, Chyla B, Punnoose E, Bolen CR, Assaf ZJ, Jiang Y, Wang J, Lefebure M, Boyer M, Humphrey K, Seymour JF
doi: 10.1200/JCO.20.00948.Visit the original publication at ncbi.nlm.nih.gov
EHA® 25 Virtual
Further Publications
Chronic Lymphocytic Leukemia
Al-Sawaf, O. et al. 2020. Fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: follow-up of efficacy and safety results from the multicenter, open-label, randomized phase III CLL14 trial. Oral presentation presented at: EHA25 Virtual; 11−21 June 2020.